Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 13/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Omigapil SCHEMBL29377962 | 1.00 | PYCR1 (0.45) | PYCR1LMNAMAOAMAOBUSP2 | |
| Omigapil SCHEMBL978229 | 0.90 | PYCR1 (0.40) | PYCR1LMNAMAOAMAOBUSP2 | |
| Omigapil SCHEMBL5953610 | 0.90 | PYCR1 (0.40) | PYCR1LMNAMAOAMAOBUSP2 | |
| Omigapil SCHEMBL29369408 | 0.90 | PYCR1 (0.40) | PYCR1LMNAMAOAMAOBUSP2 | |
| Omigapil SCHEMBL5953608 | 0.90 | PYCR1 (0.40) | PYCR1LMNAMAOAMAOBUSP2 | |
| Omigapil SCHEMBL978230 | 0.90 | PYCR1 (0.40) | PYCR1LMNAMAOAMAOBUSP2 | |
| SCHEMBL5953640 | 0.87 | PYCR1 (0.45) | PYCR1LMNAMAOAMAOBUSP2 | |
| SCHEMBL8890871 | 0.86 | DRD2 (0.41) | LMNAMAOBCYP3A4DRD2DRD4 | |
| SCHEMBL5953725 | 0.85 | PYCR1 (0.46) | PYCR1LMNAMAOAMAOBUSP2 | |
| SCHEMBL5953775 | 0.85 | PYCR1 (0.45) | PYCR1LMNAMAOAMAOBUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 319 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025088514-A1 | METTL3-METTL14-COMPLEX INHIBITORS FOR THE TREATMENT OF NEUROMUSCULAR DEGENERATIVE PATHOLOGIES CAUSED BY OR LINKED TO MUTATIONS IN THE FUS GENE | Università degli Studi di Roma “La Sapienza” (IT) | 2025-05-01 | — | — | WO | claimed |
| US-20250115659-A1 | NOVEL PROTEINS AND NUCLEIC ACID SEQUENCES AND USE THEREOF IN THE PROPHYLAXIS AND/OR TREATMENT OF CONGENITAL MUSCULAR DYSTROPHIES | UNIVERSITÄT BASEL (CH) | 2025-04-10 | — | — | US | claimed |
| EP-4486766-A1 | NOVEL PROTEINS AND NUCLEIC ACID SEQUENCES AND USE THEREOF IN THE PROPHYLAXIS AND/OR TREATMENT OF CONGENITAL MUSCULAR DYSTROPHIES | Universität Basel (CH) | 2025-01-08 | — | — | EP | claimed |
| US-20240201204-A1 | Biomarker and Druggable Target of Neurodegeneration | UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER (US) | 2024-06-20 | — | — | US | claimed |
| WO-2023165925-A1 | NOVEL PROTEINS AND NUCLEIC ACID SEQUENCES AND USE THEREOF IN THE PROPHYLAXIS AND/OR TREATMENT OF CONGENITAL MUSCULAR DYSTROPHIES | UNIVERSITÄT BASEL (CH) | 2023-09-07 | — | — | WO | claimed |
| EP-4087610-A1 | BIOMARKER AND DRUGGABLE TARGET OF NEURODEGENERATION | University Hospitals Cleveland Medical Center (US) | 2022-11-16 | — | — | EP | claimed |
| US-20120301542-A1 | EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF | PHARMA TWO B LTD. (IL) | 2012-11-29 | — | — | US | claimed |
| US-20090196875-A1 | Point mutation analysis of glyceraldehyde-3-phosphate dehydrogenase genes via allele-specific probe hybridization and/or nuclease digestion; kits; drug screening; neurodegenerative disease | Celera Corporation (US) | 2009-08-06 | — | — | US | claimed |
| EP-1686973-A4 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES | TECHNION RES & DEV FOUNDATION (IL) | 2009-03-25 | — | — | EP | claimed |
| EP-1942881-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF RENAL FAILURE | Technion Research and Development of Foundation, Ltd. (IL) | 2008-07-16 | — | — | EP | claimed |
| US-20060287401-A1 | Methods for treatment of cardiovascular disorders and diseases | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2006-12-21 | — | — | US | claimed |
| EP-1686973-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION, LTD. (IL) | 2006-08-09 | — | — | EP | claimed |
| US-20060100269-A1 | Use of 10-aminoaliphatyl-dibenz[b,f]oxepines for the treatment of degenerative ocular disorders | LAMBROU GEORGE N | 2006-05-11 | — | — | US | claimed |
| EP-1589963-A1 | USE OF 10-AMINOALIPHATYL-DIBENZ B,F OXEPINES FOR THE TR EATMENT OF DEGENERATIVE OCULAR DISORDERS | Novartis AG (CH) | 2005-11-02 | — | — | EP | claimed |
| US-20050171210-A1 | Compositions and methods for treatment of cardiovascular disorders and diseases | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2005-08-04 | — | — | US | claimed |
| WO-2005051371-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2005-06-09 | — | — | WO | claimed |
| WO-2005044255-A1 | STABILIZED PHARMACEUTICAL COMPOSITIONS | NOVARTIS AG (CH) | 2005-05-19 | — | — | WO | claimed |
| WO-2004105756-A2 | COMBINATION COMPRISING (A) A NEUROPROTECTING AGENT AND (B) AN AGENT BINDING TO GADPH AND PHARMACEUTICAL USE THEREOF | NOVARTIS AG (CH) | 2004-12-09 | — | — | WO | claimed |
| WO-2004066993-A1 | USE OF 10-AMINOALIPHATYL-DIBENZ[B,F]OXEPINES FOR THE TREATMENT OF DEGENERATIVE OCULAR DISORDERS | NOVARTIS AG (CH) | 2004-08-12 | — | — | WO | claimed |
| EP-0726265-B1 | 10-Aminoaliphatyl-dibenz(b,f)oxepins with antineurodegenarative activity | NOVARTIS AG (CH) | 2001-07-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100269-A1 | Use of 10-aminoaliphatyl-dibenz[b,f]oxepines for the treatment of degenerative ocular disorders | DBH, MAOB, AADAT | PYCR1 1050/4885LMNA 3703/4885MAOA 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.